Published in

Elsevier, Clinica Chimica Acta, (422), p. 29-39, 2013

DOI: 10.1016/j.cca.2013.03.030

Links

Tools

Export citation

Search in Google Scholar

Upper limit of normal for alanine aminotransferase: Quo vadis?

Journal article published in 2013 by Lucia Pacifico, F. Ferraro, Enea Bonci ORCID, Caterina Anania, S. Romaggioli, C. Chiesa
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Several studies suggest that a substantial number of patients with normal serum alanine aminotransferase (ALT) levels, defined by current thresholds, have ongoing hepatic necro-inflammation and fibrosis, and are at risk of liver disease progression. A major problem lies in the definition of normality. The current upper limit of normal (ULN) for ALT was established in the 1980s when reference populations were likely to include many persons with hepatitis C virus infection and nonalcoholic fatty liver disease. Because ALT may be influenced, not only by liver disease, but also by other medical conditions, changing lifestyle factors and demographic determinants, the current ALT ULN threshold has recently been challenged. This review not only highlights current evidence on why and how ALT ULN should be redefined, but also discusses the current concerns about updating the ULN threshold for ALT. (C) 2013 Elsevier B.V. All rights reserved.